These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19369668)

  • 1. Inhibitors of factor VIII in black patients with hemophilia.
    Viel KR; Ameri A; Abshire TC; Iyer RV; Watts RG; Lutcher C; Channell C; Cole SA; Fernstrom KM; Nakaya S; Kasper CK; Thompson AR; Almasy L; Howard TE
    N Engl J Med; 2009 Apr; 360(16):1618-27. PubMed ID: 19369668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII haplotypes frequencies in Tunisian hemophiliacs A.
    Elmahmoudi H; Belhedi N; Jlizi A; Zahra K; Meddeb B; Ben Ammar Elgaaied A; Gouider E
    Diagn Pathol; 2011 Jun; 6():54. PubMed ID: 21682900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients.
    Lochan A; Macaulay S; Chen WC; Mahlangu JN; Krause A
    Haemophilia; 2014 Sep; 20(5):687-92. PubMed ID: 24953131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of factor VIII in hemophilia.
    Lacroix-Desmazes S; Dimitrov JD; Repesse Y
    N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibitors of factor VIII in hemophilia.
    Santos A; Annichino-Bizzacchi JM; Ozelo MC
    N Engl J Med; 2009 Jul; 361(3):309-10; author reply 310. PubMed ID: 19610164
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.
    Pandey GS; Yanover C; Howard TE; Sauna ZE
    PLoS Comput Biol; 2013; 9(5):e1003066. PubMed ID: 23696725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review.
    Luna-Záizar H; González-Alcázar JÁ; Evangelista-Castro N; Aguilar-López LB; Ruiz-Quezada SL; Beltrán-Miranda CP; Jaloma-Cruz AR
    Blood Cells Mol Dis; 2018 Jul; 71():45-52. PubMed ID: 29544691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII haplotypes in severe hemophilia A patients in India.
    Pinto P; Ghosh K; Shetty S
    Ann Hematol; 2013 Jul; 92(7):999-1000. PubMed ID: 23262994
    [No Abstract]   [Full Text] [Related]  

  • 9. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
    Miller CH; Benson J; Ellingsen D; Driggers J; Payne A; Kelly FM; Soucie JM; Craig Hooper W;
    Haemophilia; 2012 May; 18(3):375-82. PubMed ID: 22103590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.
    Gunasekera D; Ettinger RA; Nakaya Fletcher S; James EA; Liu M; Barrett JC; Withycombe J; Matthews DC; Epstein MS; Hughes RJ; Pratt KP;
    Blood; 2015 Aug; 126(7):895-904. PubMed ID: 25617427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
    Schwarz J; Astermark J; Menius ED; Carrington M; Donfield SM; Gomperts ED; Nelson GW; Oldenburg J; Pavlova A; Shapiro AD; Winkler CA; Berntorp E;
    Haemophilia; 2013 Jan; 19(1):113-8. PubMed ID: 22958194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.
    Zhang AH; Skupsky J; Scott DW
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):114-24. PubMed ID: 19199081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of factor VIII in hemophilia.
    Eckhardt CL; Kamphuisen PW; Fijnvandraat K
    N Engl J Med; 2009 Jul; 361(3):309; author reply 310. PubMed ID: 19610163
    [No Abstract]   [Full Text] [Related]  

  • 17. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
    Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to FVIII in hemophilia A: an overview of risk factors.
    Ghosh K; Shetty S
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
    Sherief LM; Gaber OA; Youssef HM; Sherbiny HS; Mokhtar WA; Ali AAA; Kamal NM; Abdel Maksoud YH
    Ital J Pediatr; 2020 Sep; 46(1):129. PubMed ID: 32928254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.